Advertisement

The Role of Arachidonic Acid Metabolites in the Pathophysiology of Bartter’s Syndrome

  • Jeffrey S. Stoff
  • David M. Clive
  • Diane Leone
  • D. Euan MacIntyre
  • Robert S. Brown
  • Edwin Salzman

Abstract

Almost 20 years ago Frederic Bartter, John Gill, and their co-workers described an unusual form of secondary hyperaldosteronism in two children.1 Their patients had a number of clinical and metabolic abnormalities which characterize the syndrome now referred to as Bartter’s syndrome. The clinical features of this syndrome are illustrated in Table I.

Keywords

Prostaglandin Synthesis Renin Release Potassium Depletion Platelet Inhibitory Activity Antiaggregatory Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bartter FC, Pronove P, Gill JR Jr, et al: Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med 33: 811–828, 1962.PubMedCrossRefGoogle Scholar
  2. 2.
    Trygstad CW, Mangos JA, Bloodworth JMB, et al: A sibship with Banter’s syndrome: Failure of total adrenalectomy to correct potassium wasting. Pediatrics 44: 234–242, 1969.PubMedGoogle Scholar
  3. 3.
    Goodman AD, Vagnucci AH, Hartroft PM: Pathogenesis of Bartter’s syndrome. N Engl J Med 281: 1435–1439, 1969.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruden A, Aurell M, Hansson L, et al: Effect of sar’-alas-angiotensin II on blood pressure and renin in Bartter’s syndrome, before and after treatment with prostaglandin synthetase inhibitors. Scand J Clin Lab Invest 339: 543–550, 1979.CrossRefGoogle Scholar
  5. 5.
    Mizuno K, Yamazaki M, Fukuchi S: Hypotensive response to angiotensin I-converting enzyme inhibitor in Bartter’s syndrome. N Engl J Med 300: 1057, 1979.PubMedGoogle Scholar
  6. 6.
    Aurell M, Rudin A: Effects of captopril in Bartter’s syndrome. N Engl J Med 304: 1609, 1981.PubMedGoogle Scholar
  7. 7.
    Gill JR Jr, Bartter FC: Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter’s syndrome. Am J Med 35: 766–772, 1978.CrossRefGoogle Scholar
  8. 8.
    Gardner JD, Simopoulos AP, Lapey A, et al: Altered membrane sodium transport in Bartter’s syndrome. J Clin Invest 51: 1565–1571, 1972.PubMedCrossRefGoogle Scholar
  9. 9.
    Heidland A, Kreusser W, Hennemann H, et al: Excretion of the mono-and divalent ions in relation to flow rate in Bartter’s and Pseudo Bartter’s syndromes in parotid saliva. Comparative studies to the syndrome of Conn. Klin Wochenschr 50: 959–966, 1972.PubMedCrossRefGoogle Scholar
  10. 10.
    Fichman MP, Teller N, Zia P, et al: Role of prostaglandins in the pathogenesis of Bartter’s syndrome. Am J Med 60: 785–797, 1976.PubMedCrossRefGoogle Scholar
  11. 11.
    Verberckmoes R, Van Damme BB, Clement J, et al: Bartter’s syndrome with hyperplasia of renomedullary cells: Successful treatment with indomethacin. Kidney Int 9: 302–307, 1976.PubMedCrossRefGoogle Scholar
  12. 12.
    Muirhead EE, Germain G, Leach BE, et al: Production of renomedullary prostaglandins by renomedullary interstitial cells grown in tissue culture. Circ Res 31 (Suppl. II): 161–172, 1972.PubMedGoogle Scholar
  13. 13.
    Gill JR Jr, Frolich JC, Bowden RE, et al: Bartter’s syndrome: A disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 61: 43–51, 1976.PubMedCrossRefGoogle Scholar
  14. 14.
    Halushka PV, Wohltmann H, Privitera PJ, et al: Banter’s syndrome: Urinary prostaglandin E-like material and kallikrein; Indomethacin effects. Ann Intern Med 87: 281–286, 1977.PubMedGoogle Scholar
  15. 15.
    McGiff JC: Bartter’s syndrome results from an imbalance of vasoactive hormones. Ann Intern Med 87: 369–372, 1977.PubMedGoogle Scholar
  16. 16.
    Frolich JC, Wilson TW, Sweetman BJ, et al: Urinary prostaglandins: Identification and origins. J Clin Invest 55: 763–770, 1975.PubMedCrossRefGoogle Scholar
  17. 17.
    Dunn MJ, Liard JF, Dray F: Basal and stimulated rates of renal secretion and excretion of prostaglandins E2, F2 and 13,14-dihydro-15 keto F2 in the dog. Kidney Int 13: 136–143, 1978.CrossRefGoogle Scholar
  18. 18.
    Gullner HG, Cerletti C, Bartter FC, et al: Prostacyclin overproduction in Bartter’s syndrome. Lancet 2: 767–769, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Stoff JS, Maclntyre DE, Brown RS, et al: Prostacyclin overproduction in Bartter’s syndrome. Lancet 2: 1169–1170, 1979.Google Scholar
  20. 20.
    Stokes JB: Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle: Selective inhibition of the medullary portion. J Clin Invest 64: 495–502, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Higashihara E, Stokes JB, Kokko JP, et al: Cortical and papillary micropuncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production: Possible role of prostaglandins in the chloruresis of acute volume expansion. J Clin Invest 64: 1277–1287, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Oates JA, Whorton JF, Gerkens JF, et al: The participation of prostaglandins in the control of renin release. Fed Proc 38: 72–74, 1979.PubMedGoogle Scholar
  23. 23.
    Patron C, Pugliese F, Ciabattoni G, et al: Evidence for a direct effect of prostacyclin on renin release in man. J Clin Invest 69: 231–239, 1982.CrossRefGoogle Scholar
  24. 24.
    Aiken JW, Vane JR: Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 184: 678–687, 1973.PubMedGoogle Scholar
  25. 25.
    Shebuski RJ, Aiken JW: Angiotensin II stimulation of renal prostaglandin synthesis elevates circulating prostacyclin in the dog. J Cardiovasc Pharmacol 2: 667–677, 1980.PubMedCrossRefGoogle Scholar
  26. 26.
    Vander AJ, Geelhoed GW: Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 120: 399–403, 1965.PubMedGoogle Scholar
  27. 27.
    Dunn MJ: Prostaglandins and Bartter’s syndrome. Kidney Int 19: 86–102, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Dray F: Bartter’s syndrome: Contrasting patterns of prostaglandin excretion in chidren and adults. Clin Sci Mol Med 54: 115–118, 1978.PubMedGoogle Scholar
  29. 29.
    Zipser RD, Rude RK, Zia PK, et al: Regulation of urinary prostaglandins in Bartter’s syndrome. Am J Med 67: 263–267, 1979.PubMedCrossRefGoogle Scholar
  30. 30.
    Henrich W, Anderson RJ, Berl T, et al: Role of angiotensin II and prostaglandins in renal response to hypotensive hemorrhage. Am J Physiol 235: F46 - F51, 1978.PubMedGoogle Scholar
  31. 31.
    Zia P, Zipser R, Speckart P, et al: The measurement of urinary PGE in normal subjects and in high renin states. J Lab Clin Med 92: 415–422, 1978.PubMedGoogle Scholar
  32. 32.
    Galvez OG, Roberts BW, Bay WH, et al: Studies on the mechanism of polyuria and hypokalemia. Kidney Int 10: 583A, 1976.Google Scholar
  33. 33.
    Zusman RM, Keiser HR: Regulation of prostaglandin E2 synthesis by angiotensin II, potassium, osmolality, and dexamethasone. Kidney Im 17: 277–283, 1980.CrossRefGoogle Scholar
  34. 34.
    Stoff IS, Rosa RM, Epstein FH: The concentrating defect of acute potassium depletion in man is independent of renal prostaglandins. Kidney Int 16: 874, 1979.Google Scholar
  35. 35.
    Hood VL, Dunn MJ: Urinary excretion of prostaglandin E2 and prostaglandin FZ°` in potassium deficient rats. Prostaglandins 15: 273–280, 1978.PubMedCrossRefGoogle Scholar
  36. 36.
    Berl T, Aisenbery GA, Linas SL: Renal concentrating defect in the hypokalemic rat is prostaglandin independent. Am J Physiol 15: 273–280, 1980.Google Scholar
  37. 37.
    Stoff JS, Stemerman M, Steer M, et al: A defect in platelet aggregation in Earner’s syndrome. Am J Med 68: 171–180, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Stoff JS, Maclntyre DE, Salzman EW, et al: Platelet function in Butter’s syndrome: Evidence for a role of a circulating metabolite of prostacyclin, in Remuzzi G, Mecca G, De Gaetano G (eds): Hemostasis, Prostaglandins, and Renal Disease. New York, Raven Press, 1980, pp 337–345.Google Scholar
  39. 39.
    Clive DM, Leone D, Maclntyre DE, et al: A plasma factor resembling 6-oxo-PGE, inhibits platelet aggregation in Butter’s syndrome and normal man. Clin Res 29: 332A, 1981.Google Scholar
  40. 40.
    Quilley CP, Wong PYK, McGiff JC: Hypotensive and renovascular actions of 6-keto-prostaglandin El, a metabolite of prostacyclin. Eur J Pharmacol 57: 273–276, 1979.PubMedCrossRefGoogle Scholar
  41. 41.
    Wong PYK, McGiff JC, Sun FF, et al: 6-keto-prostaglandin E1 inhibits the aggregation of human platelets. Eur J Pharmacol 60: 245–248, 1979.PubMedCrossRefGoogle Scholar
  42. 42.
    Gimbrone MA Jr., Alexander RW: Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science 189: 219–220, 1975.PubMedCrossRefGoogle Scholar
  43. 43.
    Schlondorff D, Roczniak S, Satriano JA, et al: Prostaglandin synthesis by isolated glomeruli: effect of angiotensin II. Am J Physiol 239: F486–495, 1980.PubMedGoogle Scholar
  44. 44.
    Grodzinska L, Gryglewski RJ: Angiotensin-induced release of prostacyclin from perfused organs. Pharmacol Res Commun 12: 339–347, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • Jeffrey S. Stoff
    • 1
  • David M. Clive
    • 1
  • Diane Leone
    • 1
  • D. Euan MacIntyre
    • 2
  • Robert S. Brown
    • 1
  • Edwin Salzman
    • 2
  1. 1.Charles A. Dana Research Institute and the Harvard-Thorndike Laboratory of the Departments of Medicine and SurgeryBeth Israel HospitalBostonUSA
  2. 2.Department of SurgeryHarvard Medical School, Beth Israel HospitalBostonUSA

Personalised recommendations